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II. Abstract 
 
Although their existence was once controversial, cancer stem cells (CSCs) are now 
widely accepted as an important source of metastasis and drug resistance. Recent 
advances in genetic engineering allowing hierarchies of cell lineages to be traced in 
vivo have led to the discovery of specific markers of CSCs. Doublecortin-like kinase 
1 (DCLK1) is one such marker that specifically identifies chemosensory cells known 
as tuft cells in normal conditions, that become CSCs in the presence of mutation 
and inflammation in mouse models of colon and pancreatic cancer.  
Using in vitro, in vivo, and in silico techniques, the studies discussed in this PhD 
investigation demonstrate four key aspects of DCLK1 biology in injury and cancer. 
First, DCLK1 is essential to the maintenance of the intestinal epithelium and 
inducing its loss in radiation injury and colitis leads to barrier disruption, 
dysregulation of key pathways, and exacerbated disease severity. Second, DCLK1 
kinase inhibition using small molecule drugs demonstrates efficacy in models of 
colon and pancreatic cancer. Third, direct and surrogate markers of DCLK1 may 
have potential as prognostic markers in gastrointestinal cancers. Finally, DCLK1 
may have a comparable CSC/tumor supportive role in kidney cancer and likely other 
cancers outside of the GI tract.  
Despite an expanding body of knowledge concerning DCLK1, many aspects remain 
mysterious. It is clear from the literature that DCLK1 is a regulator of epithelial-
mesenchymal transition and functional stemness, but a complete understanding of 
this complex molecule will require an understanding of the role of each of its primary 
isoforms, interacting partners, and upstream and downstream signaling. Clinically, 
the development of biomarkers and targeted therapies against DCLK1 is warranted 
and has the potential to improve outcomes in subsets of cancer patients.  
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1.   Introduction: Tumorigenesis and Metastasis 
1.1 Solid tumor cancers 
In the most simplistic view of solid tumor cancers, a normal cell is converted to a 
tumor-initiating cell by the accumulation of specific mutations with functional 
consequences to the cell, resulting from heredity, environmental conditions, or 
random chance1. This cell divides rapidly, avoiding roadblocks such as programmed 
cell death (apoptosis) that prevent normal cells from dividing indefinitely, leading to 
the formation of a solid mass (tumor) within the source tissue. Cells within this mass 
may differentiate into various cell types under selection pressure (as in acquired 
resistance to chemotherapy), in response to changes to the environment, or for 
other reasons. Often solid tumors tend towards the deadly acquisition of a motile 
phenotype leading to the colonization of receptive distant organs (metastasis). This 
concept, the seed-and-soil hypothesis, was first described in 1889 by London 
surgeon Stephen Paget who noted 241 of 735 breast cancer patients had liver 
metastases at necropsy, leading him to reject the role of random chance in where 
metastases form and conjure the imagery of seeds falling ubiquitously, but sprouting 
only in fertile soil2 – a straightforward observation that describes much of the basis 
of modern cancer research.  
In the time since Paget’s hypothesis, a more complete understanding of solid tumor 
cancer biology has emerged, fueled by advances such as the discovery of genetic 
transmission of information, the structure and function of deoxyribonucleic acid 
(DNA), and other discoveries leading to a fully sequenced human genome in the 
year 20003. In this genomic era, knowledge of the molecular and cellular 
complexities of cancer biology has increased exponentially. A prominent analysis 
by Hanahan and Weinberg identifies eight hallmarks and two key enabling 
characteristics that define cancer4. The accepted hallmarks include cellular 
immortalization, angiogenesis, cell death resistance, sustained proliferative 
signaling, evasion of growth suppressors, and activation of invasion and metastasis, 
while the emerging hallmarks are deregulated cellular metabolism and evasion of 
immune-mediated destruction and the enabling characteristics are genome 
instability and tumor-promoting inflammation4. These processes and their distinctive 
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subroutines such as epithelial-mesenchymal transition, pluripotency, growth factor 
signaling, immune checkpoint, and others form a complex web (FIGURE 1)4-31 that 
partly explains why effectively treating cancer remains a challenge.  
 
 
Despite the challenge that cancer presents in its diversity, targeted cancer therapies 
including kinase inhibitors, monoclonal antibodies, immunotherapy, and emerging 
gene therapies have begun to improve patient outcomes. The first decrease in total 
cancer deaths was measured in the year 2005 with a relative survival rate of 68% 
compared to 50% for 30 years previous (1975) and 35% for approximately 50 years 
previous (1953)3, marking the beginning of a new era of improved therapies, 
biomarkers, and other advances.  
 
 
FIGURE 1. The complex web of proposed hallmarks of cancer. Through the years a 
variety of interconnected hallmarks have been proposed to explain cancer’s progression 
and intractability (figure adapted from Hanahan and Weinberg 20124). 
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1.2 Inflammation, DNA damage, and cancer initiation 
Tumor-promoting inflammation is a key enabling characteristic of cancer and a 
central focus of this PhD investigation. Inflammation is an abnormality of tissue that 
results from injury and the subsequent immune response. This process plays a key 
role in cancer initiation and progression, and occurs in response to many 
environmental causative agents linked to cancer32. Common cancer-associated 
factors that induce inflammatory injury include alcohol, tobacco, red meat, bacteria 
(e.g. Helicobacter pylori), and viruses (e.g. HPV and hepatitis)5,7,32. Often 
inflammatory agents drive acute or chronic conditions that increase the risk of 
developing cancer32. For instance, excessive alcohol consumption may lead to 
chronic pancreatitis or esophagitis which are linked to pancreatic and esophageal 
cancer respectively.  
Inflammation is a primary source of DNA damage, particularly in more susceptible 
epithelial cells. The inflammatory process leads to DNA damage via production of 
reactive oxygen or nitrogen species (ROS, RNS) in epithelial and inflammatory 
cells5. ROS/RNS are persistent enough to breach multiple barriers and penetrate 
the nucleus where they react with DNA and cause mutations5. In response, the cell 
activates its primary safeguard – the DNA damage response (DDR) pathway. In 
DDR, double strand breaks are detected by a complex of MRE11, RAD50, and 
NBS1 which then initiate key DDR components including ATM/ATR which 
phosphorylate g-H2AX, which in turn activates p53 leading to cell cycle arrest. 
During arrest, DNA errors are repaired. If repairs fail, then the damaged cell is 
terminated through apoptosis6. If DDR fails to complete its task and the damaged 
cell escapes apoptosis through the presence of p53 mutations or by other means, 
the cell may become tumorigenic. Alternative paths to somatic mutations (e.g. 
random chance, damaged DNA mismatch repair, etc.), cellular immortalization, and 
escape from apoptosis may similarly initiate tumorigenesis. 
 
1.3 The tumor microenvironment 
Although tumor initiation is a key process in cancers, the tumor microenvironment 
(TME), innate and adaptive resistance mechanisms, and the ability to invade locally 
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and spread to distant organs accounts for a large portion of their intractability. The 
TME concept describes the tumor as an organ unto itself with unique cell types and 
functions. The cell types present in solid tumors include cancer stem cells (CSCs), 
endothelial cells, pericytes, infiltrating immune cells, cancer-associated fibroblasts 
(CAFs), and stromal cells4. Understanding the functions and interplay between 
these cell types is spurring the development of a new generation of targeted 
therapies. PD-1 (e.g. PDCD1) targeted monoclonal antibodies (such as nivolumab) 
are an example of one such therapy that is demonstrating robust survival 
improvements in some patients33 by targeting the TME to allow improved immune 
infiltration.  
 
1.3.1    Cancer stem cells and EMT in the tumor microenvironment 
Although the existence of CSCs in solid tumors was once controversial, they are 
now accepted as key members of the TME that facilitate tumorigenesis, resistance, 
and metastasis. As the primary subject of this PhD investigation, they are covered 
extensively in 2.1 – 3.3. Importantly, CSCs may induce epithelial-to-mesenchymal 
transition (EMT), a process by which epithelial cells (expressing E-cadherin, 
claudins, and MUC1) begin to co-express specific transcription factors (TFs; ZEB1, 
ZEB2, Snail, Slug, and TWIST), leading to loss of polarity, remodeling of the 
cytoskeletal structure, and a phenotypic conversion to a transitional and then 
mesenchymal cell type (expressing vimentin, N-cadherin, and/or fibronectin) which 
promotes drug-resistance, intravasation through the tumor, and may ultimately lead 
to extravasation at a distant metastatic site15,34 (FIGURE 2).  
EMT can be induced by various stimuli including loss of tumor suppressor miRNAs 
such as miR-200a-c15,35,36 and activation of Tgf-b, Wnt, growth factor, and ECM-
integrin pathways15. Moreover, EMT may be reversed via mesenchymal-epithelial 
transition (MET) which can allow flexibility in the chaotic TME and in response to 
therapy, and may support invasion and clonal expansion at distant sites15. Finally, 
EMT supports other mechanisms in the TME including limiting immune infiltration 
via expression of immune checkpoint ligand PD-L119-21,23,37. Overall, EMT is 
activated in many cancer types and associated with poor survival, and anti-EMT 
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therapies have the potential to reverse drug resistance and limit 
dissemination15,17,38-40.  
1.3.2    Endothelia and pericytes in the tumor microenvironment 
The induction of angiogenesis is a hallmark of cancer dependent on the construction 
of tumor vasculature from endothelial cells with the support of specialized 
mesenchymal pericytes4, allowing increased nutrient uptake and likely supporting 
other functions. This TME component has been known for decades leading to 
effective therapies targeting vascular endothelial growth factor (VEGF)41, but the 
characteristics of tumor-associated endothelial cells are not fully elucidated4, and 
angiogenesis is not a uniform trait across cancer types. For example, renal tumors 
tend towards heavy vascularization while pancreatic tumors begin with 
angiogenesis but often become hypovascular during progression4. Finally, novel 
findings indicate that the presence of bone marrow-derived immune cells including 
FIGURE 2. Molecular, cellular, and functional characteristics of EMT. EMT is driven 
by molecular and cellular changes including expression of specific transcription factors, 
loss of tight junction proteins and associated cell junctions, and other features that lead 
to increased stemness, invasion, dissemination, and metastasis. 
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macrophages and myeloid cells support the initiation of angiogenesis in the pre-
cancer microenvironment, and some of these cells may penetrate the emerging 
tumor and convert to endothelia or pericytes to support angiogenesis4.  
 
1.3.3    Infiltrating immune cells in the tumor microenvironment 
Tumor infiltrating lymphocytes (TILs) are a diverse component of the TME, which 
include T cells, B cells, NK cells, and macrophages4. The classic view of TILs would 
suggest that their presence is an indicator that the immune system is attempting to 
prevent tumor progression. A straightforward example of this would be the process 
of major histocompatibility complex (MHC) class I presenting an antigen on the 
surface of the tumor which is then detected by a CD8+ cytotoxic T lymphocyte (CTL) 
that proceeds to force apoptosis of the tumor cell42. Counterintuitively, recent 
findings show that tumors can hijack some immune cell types and use them to 
protect themselves from immune-mediated destruction. For example, myeloid 
derived suppressor cells can block CTL and NK cell activity, and M2 macrophages 
driven by IL-4 and IL-13 signaling can promote progression and suppress anti-tumor 
TILs43. Based on an improved understanding of immune cells in the TME, methods 
to promote or inhibit TIL mechanisms (immunotherapy) are now a major focus of 
clinical oncology. 
 
1.3.4    Cancer-associated fibroblasts and stromal components 
CAFs and tumor stroma form a milieu that provides structural support in the TME 
and has functional implications for tumor progression. CAFs come in the form of 
tissue-derived fibroblasts or myofibroblasts, and those recruited to the TME 
enhance progression by increasing proliferation, angiogenesis, and invasion4. 
Moreover, evidence indicates that they can program EMT in surrounding cells44, and 
their secretion of ECM is a cause of desmoplasia in some advanced cancers such 
as pancreatic ductal adenocarcinoma4. In addition to CAFs, stroma may be recruited 
to the TME from existing tumor stroma, adjacent normal tissue, or bone marrow4. A 
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better understanding of CAFs and tumor stroma will likely be necessary to overcome 
drug delivery hurdles. 
 
1.4 Cancers of the gastrointestinal tract 
The gastrointestinal (GI) tract is uniquely exposed to inflammatory injury from shifts 
in microbiota populations45, foreign pathogens, chemicals such as alcohol, and 
other sources. The need for the GI tract to absorb fluids, digest food, regulate barrier 
permeability, and monitor microbiome populations and the presence of foreign 
pathogens among other processes, has led to exquisite cellular specialization in GI 
epithelia and rapid cell turnover. Varieties of cell types produced from rapidly cycling 
populations of stem cells perform absorptive, secretory, and other functions to 
maintain the complex balance required for homeostasis46,47. Consequently, cells in 
this dynamic system have an increased risk for DNA damage and are a major 
source of human cancer. According to the latest US statistics, GI tract cancers were 
the most category in 2017 accounting for 310,440 cases48. For individual cancers, 
colon cancer is the 4th most prevalent in the US48 and the UK49. These cancers are 
exceptionally deadly, with colon and pancreatic cancers ranking 2nd and 3rd in 
mortality respectively, behind lung cancer in the US48, and 2nd and 5th in the UK49. 
US and UK incidence, mortality, 5-year survival rates, tumor staging categories, 
TNM classification, prevalent subtypes, and select risk factors for colorectal, 
pancreatic, gastric, and esophageal cancer are tabulated in Appendix I. 
 
1.4.1    Colorectal cancer 
Colorectal cancer (CRC) develops from normal epithelial cells in stages beginning 
with an abnormal crypt which transitions to an adenoma and then adenocarcinoma. 
This process is driven by mutations and epigenetic alterations which may arise in 
the presence of inflammatory injury. The risk factors for sporadic CRC are partly 
modifiable and include obesity, alcohol, tobacco, and red meat50. CRC may also 
arise due to hereditary conditions including Lynch syndrome, which results from 
mutations in mismatch repair genes, or familial adenomatous polyposis (FAP) which 
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results from germline mutations in the APC gene50. APC is a tumor suppressor that 
is considered a CRC gate-keeper and mutated in up to 70% of CRCs51-53. The 
second most prevalent set of mutations in CRC are KRAS mutations, which are 
often single nucleotide polymorphisms (SNPs) affecting amino acids G12 or G13. 
Estimates for the prevalence of these mutations range from 30 – 60%54, and they 
are associated with increased mortality especially in metastatic cancer55,56. As in 
other cancers, p53 tumor suppressor mutations are also exceptionally common57. 
In addition to this mutational landscape that demonstrates additive disease 
severity58, CRC is characterized by an EMT phenotype59,60 linked to survival 
(FIGURE 3). As discussed previously, EMT is a source of metastatic 
transformation61 associated with CSCs which are key players in colorectal 
tumorigenesis and progression59,60,62. 
Treatment strategies for CRC vary by the location and disease severity. Where 
possible, surgical resection is favored, and following rectal cancer resection, 
neoadjuvant therapies can be used to improve outcomes. A variety of 
chemotherapies are available for CRC, but adjuvant therapies are typically not given 
in non-metastatic disease in the absence of significant risk factors. The mainstay for 
patients with metastatic CRC (mCRC) are combination treatments such as 
leucovorin, 5-fluorouracil, and either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI). 
A. B. 
FIGURE 3. EMT predicts poorer survival in CRC. Analysis of TCGA’s colorectal 
cancer RNA-seq datasets (n=291) demonstrates that increased EMT marker 
expression (calculated as previously described61) predicts poor overall (A) and 
recurrence-free survival (B) with an approximately 30-month decrease in median 
survival for both comparisons. 
* P=0.008 * P=0.014 
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Additionally, targeted therapies may be used against tumors with receptive 
genotypes, such as anti-EGFR monoclonal antibodies in RAS wild-type CRC50. 
Despite the availability of broad spectrum and targeted therapies, disease-specific 
mortality remains high at up to 50%50, and improvements in socioeconomic 
conditions worldwide will likely increase CRC incidence. However, an improved 
understanding of the molecular and cellular traits that define CRC, and the 
development of novel biomarkers and therapeutic strategies may lead to 
improvements in patient outcomes. 
 
1.4.2    Other gastrointestinal tract cancers 
Other common cancers of the GI tract include esophageal cancer, stomach 
adenocarcinoma, and hepatocellular carcinoma. Like the intestine, the esophagus 
and stomach have specialized cell types to aid in absorption, secretion, surveillance, 
and other processes. Both the stomach and esophagus are susceptible to the pre-
neoplastic formation of pseudo-intestinal tissue characterized by an intestinal crypt 
type architecture and the presence of mucin-secreting goblet cells63,64. This 
intestinal metaplasia is linked to Helicobacter pylori and other inflammatory agents 
and affected tissue expresses intestinal stem cell markers suggesting its 
appearance is not coincidental63. Like colorectal and pancreatic cancers, 
esophageal and stomach cancers also express EMT markers which are capable of 
driving metastasis in their respective tumors65,66.  
 
1.4.3    Pancreatic cancer 
Pancreatic cancer, the most common subtype of which is pancreatic ductal 
adenocarcinoma (PDAC), is a relatively low incidence cancer with exceptionally 
high mortality. PDAC’s dismal <7% 5-year survival rate is partly due to limited 
symptoms in patients during pre-cancerous and early stage disease, aggressive 
invasion, early dissemination, and resistance to therapy67. Known PDAC risk factors 
are pancreatitis, age, tobacco use, heavy alcohol consumption, obesity, diabetes, 
and a family history of the disease. Persons from low risk locales who immigrate to 
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high risk locales adopt the high risk of disease within decades suggesting the 
importance of environment to PDAC67. Currently, surgery during early disease is the 
only effective intervention38, enabling an additional 11 months of survival (median) 
in stage I or II disease68. However, despite this advantage, the disease is so often 
fatal that global statistics show little difference between PDAC incidence and 
mortality69, and incidence continues to climb due to improved longevity. 
Due to its various functions, the pancreas is comprised of a variety of cell types with 
one or both of two epithelial types (acinar and ductal) playing a key role in PDAC 
development. In genetically engineered mouse models, the introduction of KRAS 
activating mutations with the loss of p53 or another relevant tumor suppressor in 
either cell type is sufficient to induce pancreatic ductal adenocarcinoma 
(PDAC)39,70,71. This dual cell origin may be explained by the process of acinar to 
ductal metaplasia (ADM), in which injury to the pancreas causes destruction of ducts, 
and acinar cells convert to compensate for the loss. ADM may also lead to the 
generation of pancreatic intraepithelial neoplastic lesions (PanINs) which are the 
forbears of PDAC72. Although the cellular processes leading to PDAC are now better 
understood, strategies for detecting and blocking these processes at the molecular 
level will be necessary to improve outcomes due to PDAC’s aggressiveness. 
On the molecular level, PDAC shares many similarities with CRC. Although PDACs 
rarely demonstrate mutations to APC, KRAS G12/G13 and p53 mutations are 
present in most PDACs. By some estimates, KRAS mutations in PDAC may reach 
levels >95%. PDACs exhibit high levels of cellular heterogeneity and are 
characterized by an EMT phenotype which is linked to early metastatic 
progression39,73. These characteristics along with PDAC’s fibrotic microenvironment 
(desmoplasia) have complicated therapy. The most commonly used PDAC 
chemotherapy, gemcitabine, provides a small survival advantage and modestly 
improves quality of life. More recently, albumin-bound paclitaxel (Abraxane™), anti-
EGFR therapy, and combination leucovorin, 5-FU, irinotecan and oxaliplatin 
(FOLFIRINOX) have come into use and demonstrate benefits beyond gemcitabine 
alone in suitable candidates67. However, despite these treatment options and 
available surgical techniques, survivability remains dismal.  
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1.5 Cancers of the urinary tract 
Like the GI tract, the urinary tract (UT) depends on specialized cell types to monitor 
its microbiome74 and maintain homeostasis, and evidence is beginning to 
accumulate that UT cancers are associated with changes in the UT microbiome74. 
Unlike infections of the GI tract, urinary tract infections (UTIs) often present with 
obvious symptoms allowing more efficient treatment, and epidemiological studies 
suggest that treatment of UTIs with antibiotics is inversely associated with bladder 
cancer75. This indirectly implicates inflammation as a key process in UT cancers, 
which is also supported in kidney cancer, which is associated with exposure to 
carcinogens including tobacco, radiation, viral infection, and other inflammatory 
factors76. US and UK incidence, mortality, 5-year survival rates, tumor staging 
categories, TNM classification, prevalent subtypes, and select risk factors for kidney 
cancer are tabulated in Appendix I. 
 
1.5.1    Renal cell carcinoma 
Renal cell carcinoma (RCC) is the most common UT cancer and the most common 
subtype is clear cell RCC (ccRCC) followed by the papillary (pRCC) and 
chromophobe (chRCC) subtypes77. RCC is more common in males and increases 
in prevalence with age. Major risk factors for RCC include obesity, hypertension, 
and tobacco consumption. Partial or radical nephrectomy is the primary therapy for 
most patients with localized RCC because it rarely presents bilaterally, and in 
patients with non-localized disease, surgery can reduce progression. However, 
even radical nephrectomy with curative intent in localized RCC leads to a >30% 
chance of metastasis77. Despite the availability of advanced surgical options and 
many chemotherapies, survival of patients with RCC is relatively low and becomes 
dismal with minor local spread. Like the GI cancers discussed previously, RCCs are 
often characterized by an EMT phenotype40,78,79 which may explain their metastatic 
potential. Additionally, they maintain a hypoxic microenvironment and frequently 
develop resistance to chemotherapies.  
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On the molecular level, mutation to the Von-Hippel Lindau tumor suppressor gene 
(VHL) is the most common event in RCC, which in combination with other VHL loss 
mechanisms, represents a unifying factor in RCC development. As a consequence 
of VHL loss, hypoxia-inducible factors (HIFs) avoid ubiquitin-mediated degradation 
and drive hypoxia and angiogenesis77. Despite the importance of these processes, 
they are insufficient to initiate and maintain RCC on their own. Large scale 
sequencing projects to better understand other contributors have narrowed in on 
the PI3K/AKT pathway which is frequently mutated and global hypomethylation 
mediated by SETD2 and chromatin remodeling-associated factors80, but a more 
complete understanding of RCC remains elusive.  
 
2 The Cancer Stem Cell Hypothesis  
2.1 Normal stem cells 
Stem cells are undifferentiated cells defined by their ability to originate all cell types 
of their substrate tissue (pluripotency) including themselves (self-renewal). They are 
best known for their role in embryonic development (embryonic stem cells), but also 
reside in adult tissue (somatic or normal stem cells; NSCs). Because most tissue 
requires specialized cells to function effectively, stem cells have a major impact on 
homeostasis, the response to environmental changes, and injury response.  
 
2.1.1    Pluripotency, self-renewal, and differentiation 
The modern concept of a stem cell, defined by self-renewal ability and pluripotency, 
originated with the discovery that bone marrow cells could rescue lethally irradiated 
mice from death by restoring the function of the hematopoietic system81. Additionally, 
the presence of transplantable colonies was observed in the spleens of the injured 
mice81. This finding led to the first complete stem cell lineage – the hematopoietic 
stem cell (HSC) and its progenitors82. HSCs differentiate into ever more specific cell 
types until reaching a terminal, fully-differentiated type83,84, and the pathways that 
drive their differentiation are now known in exquisite detail due to an accessible 
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niche (blood), cell-surface markers that allow lineage tracking, and a long history of 
experimental manipulations using fluorescence-activated cell sorting (FACS).  
In contrast to HSCs, identification of stem cells and their lineages in solid tissue has 
been elusive81. This is partly because removing the cell from its niche and recreating 
a complicated microenvironment ex vivo is fraught with difficulties. However, NSCs 
have been identified in intestinal and hair follicle epithelia. Although stem cells have 
often been imagined as singular populations, findings in both of these tissues 
suggest the presence of multiple stem cell types – a rapidly cycling type and a slowly 
cycling (quiescent) type85. Both stem cell niches are structurally similar and support 
rapid regeneration necessary for response to damage from exposure to pathogens, 
radiation, and other environmental factors. Notable research suggests that the 
quiescent cell type may repopulate the tissue in the event of significant injury which 
will selectively damage proliferating cells86,87. This combination of quiescence and 
stemness may be a key factor in the emergence of CSCs. 
 
2.2 Cancer stem cells 
Until recently, clonal evolution (the stochastic model) was the primary hypothesis 
for the functional and molecular variation (heterogeneity) found in tumors88. This 
model posits that most or all cells can potentially initiate tumorigenesis and do so 
due to the accumulation of mutations and other molecular changes leading to 
polyclonal subpopulations of cells over time89 (FIGURE 4A). The Vogelstein group 
first proposed this model in 1987 based on their studies of CRC progression. 
Specifically, they proposed that CRC begins with a molecular event (such as 
hypomethylation) leading to a benign tumor (adenoma), followed by oncogenic 
KRAS mutation, and then an alteration leading to subsequent tumor suppressor 
loss89. Since the cells arising from the original source in this model would acquire 
different mutations or other molecular alterations, this might explain the polyclonal 
nature of many tumor types.  
A more recent hypothesis used to explain the polyclonal nature of tumors is the 
cancer stem cell hypothesis (hierarchical model)88,90. CSCs are largely expected to 
function like NSCs which produce progeny that form the bulk of their source tissue. 
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Although progeny originate from a single source, differentiation leads to a variety of 
different cellular phenotypes (FIGURE 4B). Like NSCs, CSCs self-renew and 
produce every cell type that forms the tumor. The concept of CSCs was first 
proposed in blood cancers during the 1960s-70s, but compelling evidence of CSCs 
has only accumulated within the past 20 years88. The fusion of new knowledge of 
CSCs, clonal evolution, the TME, and other factors has led to a better understanding 
of tumor initiation.  
FIGURE 4. Comparison of the stochastic and hierarchical models of tumorigenesis. 
A. The stochastic model assumes that every cell type can become tumorigenic under 
certain conditions. This begins with a deleterious event such as a mutation, but a single 
event is unlikely to initiate tumorigenesis. Instead, an accumulation of events is thought 
responsible. Moreover, this model predicts homogeneous and heterogeneous tumor types. 
B. The hierarchical model predicts that tumors arise when a tumorigenic event affects a 
specific cell type which gains the ability to self-renew and continuously produces the 
progeny that form the tumor bulk (e.g. a CSC). This cell can be a hijacked normal stem cell 
or other cell type. The assumptions of this model support heterogeneity as a characteristic 
of all CSC-driven tumors. The assumptions of the stochastic and hierarchical models 
together, predict metastatic progression and the possibility of multiple CSC types within the 
same tumor (adapted from Bradshaw et al, 201690).  
		 	 	 15	
2.2.1    CSCs and tumor initiation 
The first experimental proof of CSCs came in the mid-1990s when it was determined 
that CD34+/CD38- acute myeloid leukemia (AML) cells could be transplanted into 
immune deficient mice, populate the bone marrow, and disseminate consistent with 
human disease, while other populations could not88,91,92. This subpopulation 
demonstrated self-renewal and the ability to give rise to other populations of 
leukemia cells as expected of a CSC93. Moreover, since CD34 is a marker of HSCs, 
this suggested that AML could originate with the direct transformation of HSCs. 
Following findings of CSCs in AML and other blood cancers, the search for CSCs 
in solid tumors began. The first solid tumor CSC population identified was 
CD44+/CD24- breast cancer cells which were able to form subcutaneous tumors in 
immunocompromised mice from <1000 cells88,92,94. Soon, highly potent CD44+ CSC 
populations were discovered in prostate, colon, pancreatic, and other cancers88,92 – 
and a second marker, CD133, was found to mark CSCs in brain, colorectal, and 
lung cancer92. Ultimately, the discovery of these CSC subpopulations was a function 
of convenience as CD44 and CD133 are extracellular and easily targeted for FACS 
cell sorting which could be followed by in vitro or in vivo transplantation. Further 
investigation led to the discovery of new CSC markers such as aldehyde 
dehydrogenase (ALDH), drug transporter ABCG2, and focal adhesion kinase (FAK). 
Although all of these enriched solid tumor subpopulations demonstrated significant 
CSC properties, none could rightfully be described as a pure population of CSCs92 
– which could theoretically give rise to spheroids in vitro and tumors in mice from a 
single cell. 
In recent years, genetically engineered, Cre-recombinase driven lineage tracing 
mouse models have revolutionized CSC discovery (FIGURE 5). The Clevers group 
demonstrated the value of this technology in 2009 by deleting the Apc tumor 
suppressor gene in a previously identified population of intestinal NSCs marked by 
G-protein coupled receptor Lgr5 (Lgr5CreApcflox/flox)14. The induced loss of Apc in the 
Lgr5+ NSC in this model was sufficient to initiate tumorigenesis. Although the entire 
tumor originated from Lgr5+ cells, FACS analysis of tumors 36-days post Apc 
deletion demonstrated a 6.5% population of Lgr5+ cells14. This and later studies 
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would confirm that Lgr5+ cells not only initiate tumors in conditions of Apc loss, but 
also reproduce themselves and the additional cell types that maintain 
tumorigenesis13,14. These and similar studies demonstrated for the first time that a 
single event in a receptive cell type could consistently drive CSC transformation 
resulting in solid cancer tumorigenesis. 
 
 
FIGURE 5. Cre/flox lineage tracing models. On the gene level, Cre is often inserted 
upstream of an internal ribosome entry site (IRES) which allows Cre and the expression of 
a reporter (e.g. GFP) to be concurrently driven by a gene promoter of interest. When 
resulting Cre recombinase encounters two loxP sites in another construct, it deletes the 
contents between them by recombination. This can activate a persistent reporter under the 
control of Rosa26 (lineage trace), knockout a gene, or activate a knock-in mutation. On the 
organism level, this is achieved in mice by crossing a Cre mouse model with a loxP (flox) 
mouse model. On the cellular level, the Cre/flox system activates an event of interest under 
the control of the gene promoter in a time-dependent manner, as shown for the 
reporter/lineage tracing combination above. Depending on the Cre construct, the resulting 
activity can be constitutive or chemically inducible. 
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2.2.2    CSCs, resistance, and tumor progression 
Aside from their established role in initiating cancer, CSCs are central factors in drug 
resistance and disease progression88,92. Unlike cells that form the bulk of the tumor, 
CSCs may not be highly proliferative while many drug therapies primarily target 
rapidly dividing cells. For example, taxanes target microtubules which are 
accessible during mitosis, and consequently would be less effective against 
quiescent CSCs. Moreover, CSCs are often molecularly empowered to avoid 
destruction and may express multi-drug resistance factors and immune checkpoint 
proteins allowing drug efflux before damage and shielding their presence from the 
immune system. On a more basic level, CSCs drive tumor heterogeneity which 
complicates all non-surgical therapies. Following therapy, most tumor cells may be 
effectively destroyed, but remaining CSCs are left behind and may be able to initiate 
recurrence (FIGURE 6).  
CSCs are consistently linked to EMT in solid tumor cancers. As discussed 
previously, EMT fuels cancer migration and invasion, and in combination with CSC 
properties of self-renewal, pluripotency, and drug-resistance, is thought to be key in 
the establishment of metastases92. Though subject to debate, EMT itself may confer 
a CSC identity to otherwise differentiated tumor cells (dedifferentiation)95. Finally, 
both EMT and CSCs are associated with a TME that includes angiogenesis, hypoxia, 
increased stromal elements, and the presence of extracellular matrix88, which may 
be key in the CSC response to therapy and subsequent progression. Overall, 
identification of specific CSC targets, factors controlling their self-renewal, 
properties of their niche, checkpoints for their rate of proliferation, and biomarkers 
for determining patient candidates for therapy will be essential to progress in this 
area. 
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FIGURE 6. CSCs are a source of drug resistance and disease progression. A. CSCs 
are a subpopulation of tumor cells defined by their ability to reproduce themselves and all 
tumor progeny. They are often tumor-initiating cells and are slowly-dividing (quiescent). B. 
A majority of 1st line chemotherapies are preferentially targeted towards rapidly dividing cells 
and may destroy the tumor bulk while CSCs resist damage or are unable to be drugged due 
to off-target toxicity to more slowly dividing normal cells. C. The majority of targeted 
therapies are not specific to CSCs, although they may remove 1st line therapy-resistant 
tumor bulk. D. CSCs that resist therapy are primed to become deadly through enhanced 
drug resistance and invasive capabilities, often mediated by EMT, and as a result of 
selection. 
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3 Doublecortin-like kinase 1: a Specific Marker of 
Cancer Stem Cells 
3.1 The doublecortin-like kinase 1 (DCLK1) gene 
Human doublecortin-like kinase 1 (DCLK1) was first identified in fetal brain tissue, 
localized to chromosome 13, and found to encode four isoforms termed a-Long 
(Isoform 2), a-Short (Isoform 1), b-Long (Isoform 4), and b-Short (Isoform 3) based 
on the location of their promoter (a or b) and C-terminus length (Long or Short)96. 
DCLK1’s a-promoter driven isoforms are comprised of two N-terminal microtubule-
binding domains with high homology to doublecortin (DCX), a serine/proline-rich 
region suspected to participate in autophosphorylation, a kinase domain with 
homology to the CAMK kinase family, and a C-terminus region96,97. DCLK1’s b-
promoter driven isoforms are nearly identical to the a-promoter isoforms but lack N-
terminal DCX domains96 (FIGURE 7).  
DCLK1-Long (AL/BL) isoforms result from alternative splicing between exons 16 
and 17. Interestingly, this is a binding site for CTCF, a TF known to guide 
transcription by binding to effectively create a “roadblock” to exon skipping98 
(FIGURE 8). To test if CTCF regulates DCLK1 alternative splicing, RNA-Seq 
FIGURE 7. The domain organizations of the primary isoforms of DCLK1. a-
promoter driven isoforms of DCLK1 (AL/AS or 2/1) share microtubule-binding (DCX) 
domains at their N-terminus and have a molecular weight of 82 kDa. b-promoter driven 
isoforms (BL/BS or 4/3) share a shortened N-terminus and have a molecular weight of 
52 kDa. Isoforms are described as “Long” or “Short” based on the length of their C-
terminus and all isoforms share a portion of the serine/proline-rich (SP-Rich) domain 
and the complete kinase domain (Source: Uniprot). 
DCLK1:O15075 
Long 
Short 
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expression data generated by TCGA for ccRCC80, pRCC99, PDAC100, colon 
adenocarcinoma57, lung adenocarcinoma101, and lung squamous cell carcinoma102 
was downloaded from the UCSC Cancer Genome Browser103, each cancer type 
was grouped by CTCF expression, and percentages of expression for each 
available DCLK1 transcript (AL, BL, AS) were compared. In all cases, DCLK1-AL/BL 
percentages increased proportionally with the CTCF loss. Moreover, the DCLK1-
L/S expression ratio in ccRCC increased with CTCF loss and tumors with the lowest 
CTCF levels had a 160:1 long/short expression ratio (FIGURE 8). This suggests 
that CTCF binding and related regulatory processes are factors in DCLK1 
alternative splicing. 
FIGURE 8. Exon/intron organization and regulation of alternative splicing of 
DCLK1 primary transcripts by CTCF. Top Panel: The a-promoter encodes a transcript 
from 18 exons (AS) and the b-promoter encodes a transcript from 14 exons (BS). Also, 
due to an alternative splicing (exon skip) event in the vicinity of a CTCF binding site, the 
a-promoter encodes a separate transcript from 17 exons (AL) and the b-promoter 
encodes a similar alternative transcript from 13 exons (Source: ENSEMBL). Bottom 
Panel: Analysis of RNA-Seq data from TCGA suggests that DCLK1-Long transcripts are 
produced in kidney, colon, pancreatic, and lung cancers when transcription factor CTCF 
is unable to bind its site between DCLK1 exons 16 and 17. 
7.6 
kB 
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kB 
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The earliest studies of DCLK1 indicated its expression in the brain, but 
demonstrated no comparable expression elsewhere96,97. As a result, it was originally 
thought to be a brain-specific gene, and was studied purely in this context for almost 
a decade after its discovery. Studies utilizing in vitro models with a focus on neural 
development soon demonstrated molecular properties for DCLK1 consistent with its 
protein domains including: kinase activity104,105; microtubule-binding, bundling, and 
elongation activity104; autophosphorylation and phosphorylation of substrates104,106; 
and other activities104-107. Initial studies of DCLK1’s function in the brain 
characterized the protein as a regulator of mitosis and differentiation in neural 
progenitor cells and axonal transport in neurons108-110. Perhaps as an evolutionary 
redundancy, DCLK1 and DCX are able to substitute for one another in stabilizing 
microtubules and modulating axon genesis and cortical neuron migration109,110. 
Moreover, loss or gain of DCLK1 function in neural progenitors leads to 
differentiation suggesting that DCLK1 is a determinant in this process108. Finally, 
global knockout of DCLK1’s a-promoter isoforms is not lethal or damaging in mouse 
models unless combined with concomitant perturbation of DCX111,112. 
Given previous northern and western blotting results suggesting minimal to no 
expression of DCLK1 outside of the brain, it was not reported in other contexts until 
2006 when it was identified as a marker of specific cells in the base of the intestinal 
crypts of Lieberkühn and the gastric stem cell niche by transcriptome-wide analysis 
of micro-dissected tissue. These cells were often localized to the suspected location 
of the multipotent reserve stem cell in the intestine and displayed a poor ability to 
uptake the proliferative marker bromodeoxyuridine in both the intestine and stomach 
indicating quiescence113. Given these reported GI stem cell-like properties114, these 
findings formed the basis for investigations of the role of DCLK1 in the GI tract. 
 
3.2   A unique lineage of DCLK1+ cells in the gastrointestinal tract 
To better understand the role of the DCLK1+ cell in the gut, studies were undertaken 
to assess its role at homeostasis and in the response to DNA-damaging injury using 
the well-characterized total body irradiation model. To test if the DCLK1+ cells in the 
intestinal crypt stem cell region were resistant to radiation injury, mice were 
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irradiated at a highly damaging dose of 6 Gy. Although the DCLK1+ cells 
demonstrated hallmarks of DNA damage 6 hours after irradiation, they did not 
demonstrate apoptotic features like surrounding DCLK1- cells. Moreover, 24 hours 
after irradiation they were found to be either apoptotic or mitotic115 suggesting that 
some of the DCLK1+ cells could avoid the mechanisms that designated DNA 
damaged cells for destruction. However, at a lethal dose of 12 Gy, which is sufficient 
to destroy most intestinal crypts through stem cell eradication, regenerated crypts 
demonstrated no expression of DCLK1 protein115. These findings suggested that 
while DCLK1 marked a unique cell population with resistance to apoptosis after 
DNA-damaging radiation, it was not a marker of NSCs at homeostasis leading to 
the conclusion that it might mark a reserve stem cell that functioned during 
catastrophic injury.  
Further studies were conducted to test the reserve stem cell hypothesis and 
demonstrated strong similarities in pancreas116 and stomach117. Dclk1+ intestinal 
and pancreatic epithelial cells isolated from normal mouse demonstrated clonogenic 
capacity in vitro and in vivo – an important property of stem and progenitor cells115,116. 
However, despite stem-like functionality in the Dclk1+ cell, this concept was 
effectively refuted by methodical demonstration that Dclk1 marked a novel lineage 
of terminally differentiated, secretory tuft cells46,118 (FIGURE 9)119. The intestine had 
been previously defined in the literature by markers of four fully differentiated 
lineages of Paneth (antibiotic secretions), enteroendocrine (hormone secretions), 
and goblet (mucus secretions) cells and absorptive enterocytes46. Previous studies 
focused on Dclk1 had attempted to co-localize markers for these known cell types 
and failed. Therefore, it was incorrectly concluded that Dclk1 marked 
undifferentiated cells because the potential for a fifth lineage of cells had not been 
adequately considered. Building on the findings of the new lineage, reports of 
apparent Dclk1+ tuft cells in the stomach117,120 and pancreas70,121 emerged 
suggesting their presence throughout the GI tract. 
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Tuft cells, also known as brush cells, have been found in various tissues and were 
first described in 1956, but despite knowledge of the existence of this cell type, the 
lack of a specific marker had hindered research for over 50 years46. With 
confirmation of a new lineage of GI tuft cells defined by the expression of Dclk1, 
studies to understand their functionality at homeostasis, in injury, and in neoplasia 
began. Tuft cells, whose identity had previously been muddled with the secretory 
enteroendocrine cell lineage, had already been suspected of secreting endogenous 
opioids122 and were quickly confirmed to secrete endorphins46. Moreover, having a 
specific tuft cell marker allowed the confirmation of additional chemo-
signaling/sensory characteristics long suspected. In particular, Dclk1+ tuft cells 
express taste receptors (TRPM5, TAS1R1/3) and cyclooxygenase enzymes (COX-
1/2) which may contribute to chemosensory function28. However, the biggest leap 
in understanding tuft cell function was reported in late 2015 with the publication of 
concurrent papers outlining the mediator role of the Dclk1+ tuft cell lineage in 
response to intestinal parasite infection123,124. Both papers demonstrated that Dclk1+ 
tuft cells maintain resident innate immune cells at homeostasis via IL-25 secretion 
and increase secretion in response to infection to activate tissue-resident group 2 
innate lymphoid cells (ILC2s). The activated ILC2s respond by recruiting type II 
helper T cells which secrete IL-4 and IL-13. The secreted IL-4/IL-13 induces rapid 
FIGURE 9. IHC of DCLK1+ 
tuft cells‡.  
A. IHC staining of DCLK1 in 
normal duodenal epithelium 
displaying the characteristic 
apical “tuft” structure.  
B-C. IHC staining of DCLK1 
in normal adjacent pancreatic 
epithelium and pancreatic 
cancer epithelium 
respectively demonstrating 
the presence of DCLK1+ tuft 
cells in both conditions.  
D-E. IHC staining of DCLK1 
in cancerous breast duct-like 
epithelium showing tuft-like 
DCLK1+ cells.  
	
‡Sources: Human Protein Atlas119 (A,D-E) and an 
unpublished pancreatic cancer tissue microarray 
stained in the Houchen laboratory (B-C).	
		 	 	 24	
tuft cell differentiation from the stem/progenitor zone leading to hyperplasia123,124. 
The result is an expansion of sensory tuft cells which can presumably sense 
progress in the immune response to infection and activate or deactivate that 
response as necessary. Interestingly, a subsequent study found that knocking out 
tuft cell-specific taste receptor TRPM5 blocked their secretion of IL-25 in response 
to infection125, suggesting that tuft cells activate the immune system after “tasting” 
the presence of infection. These findings highlight the importance of tuft cells in the 
inflammatory response which is a key factor in tumor-initiation and progression in 
GI and other cancers126,127. 
 
3.3 DCLK1 marks tumor-initiating cancer stem cells in the 
gastrointestinal tract 
The first investigation of DCLK1 in cancer was conducted in 2008 and focused on 
the ApcMin/+ mouse model of intestinal polyposis115 – a model relevant to human 
CRC. As discussed previously, APC is the most commonly mutated gene in CRC 
patient tumors128, frequently leading to loss of APC and potential intestinal 
tumorigenesis. Immunohistochemistry revealed that DCLK1 was expressed in 
isolated cells in ApcMin/+ adenomas. Notably, these cells were found to be quiescent 
as measured by proliferative marker PCNA. Additionally, while in normal tissue 
DCLK1+ cells demonstrated cytoplasmic expression of b-catenin – a key protein 
that supports CSCs and cooperates with APC in colonic tumorigenesis and 
metastasis115 – in ApcMin/+ adenomas DCLK1+ cells presented with nuclear 
translocation of activated b-catenin115. Therefore, it was hypothesized that DCLK1 
marked CSC or CSC-like cells in intestinal cancers. 
In the coming years, additional studies provided support for the DCLK1+ CSC 
hypothesis129-135, but confirmation was elusive. Concurrently, the use of inducible 
Cre recombinase models, which allow specific tracing of cell lineages (FIGURE 5), 
was increasing. In 2012, Nakanishi et al reported a tamoxifen-inducible DCLK1 a-
promoter-driven Cre recombinase model (Dclk1Cre-ERT2) that allowed DCLK1+ cell 
lineage tracing. Crossing this model with the ApcMin/+ model of intestinal cancer 
confirmed the hypothesis that DCLK1 is specifically expressed in CSCs in conditions 
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of Apc loss. Specifically, intestinal NSCs (Lgr5+) give rise to DCLK1+ cells which 
produce progeny to form the ApcMin/+ polyps. Moreover, diphtheria-toxin mediated 
ablation of DCLK1+ cells in this model results in polyp collapse and returns 
surrounding tissue to an approximately normal architecture136. Overall, these 
findings suggested that DCLK1 not only marks CSCs in conditions of Apc loss, but 
that targeting the DCLK1+ cell for destruction may partly reverse colon cancer 
progression. Soon after, Westphalen et al reported a separate DCLK1-driven Cre 
recombinase model utilizing artificial chromosome technology (Dclk1Cre-ERT)10. 
Unlike the Nakanishi et al model, the engineering in this model does not result in 
the deletion of a DCLK1 allele via the knock-in process. When crossed with an 
Apcflox/flox mouse, which results in specific loss of APC in DCLK1+ cells globally, this 
model did not appear to result in tumor initiation. To investigate further, Westphalen 
et al induced conditions mimicking inflammation (colitis) using dextran sulfate 
sodium (DSS) – a chemical irritant that cannot initiate cancer on its own. With the 
addition of DSS, tumors formed rapidly in the Dclk1Cre-ERTApcflox/flox mice in 
agreement with the Nakanishi et al findings. Together these findings confirm that 
DCLK1 may serve as a specific CSC marker in colon cancer10. However, the 
application of these concepts outside of inflammation-associated colon cancer 
should be approached cautiously because the ApcMin/+ model utilized by Nakanishi 
et al demonstrates significantly reduced tumorigenesis in germ-free conditions137. 
KRAS is the most frequently mutated gene in pancreatic cancer and SNPs present 
at its 12th or 13th amino acid (G12D, G12V, G13D, G13D) result in constitutive over-
activation of the protein which signals downstream to a large number of pro-
oncogenic pathways including PI3K, AKT, mTOR, anti-apoptosis, and others138,139. 
Tantalizing evidence for a direct link between DCLK1 and KRAS came from 
CRISPR-based mutagenesis studies in SW48 KRAS wild-type colon cancer cells. 
When KRAS G12D was introduced, DCLK1 was determined to be the most 
overexpressed protein in the proteome by mass spectrometry. Although DCLK1 had 
been linked to KRAS previously70,140,141, this study was unique because CRISPR 
allowed the insertion of an activating mutation without unnatural levels of 
overexpression, demonstrating that the presence of KRAS mutation leading to 
constitutive KRAS activation, as it occurs in human cancer development, 
		 	 	 26	
preferentially induces DCLK1. To investigate the hypothesis that DCLK1 might also 
mark CSC-like cells in KRAS-mutant pancreatic cancer, Westphalen et al crossbred 
their existing Dclk1Cre-ERT mouse model with a model that inserts a Kras G12D point 
mutation in Kras exon 1 and a stop codon upstream resulting in constitutive 
activation in the presence of Cre recombinase (KrasLSL-G12D). Similar to their Apc-
loss colon model10, introducing KRAS G12D in the DCLK1+ cell did not result in 
spontaneous pancreatic cancer142. However, inducing pancreatitis in the same 
model using the inflammatory peptide cerulein, led to the formation of pancreatic 
cancer that could be specifically traced from the DCLK1+ cell142. These findings 
demonstrated that the DCLK1+ cell may serve a CSC-like role in pancreatic cancer 
similar to its role in colon cancer.  
 
3.4    Functional implications of DCLK1 expression in cancers 
Gene manipulation studies have demonstrated that beyond its CSC marker role 
downstream of oncogenic mutations, DCLK1 also regulates key cancer traits 
including EMT, stemness/pluripotency, and expression of tumor suppressor 
microRNAs (miRNAs). DCLK1 downregulation was originally reported to result in 
upregulation of tumor suppressor miRNAs Let-7a, miR-144, miR-145, and miR-
200130-132,140. More recent reports have linked DCLK1 to the regulation of other 
miRNAs or vice-versa, including miR-137, miR-363, miR-424, miR-448, and miR-
613143-147. Downregulation of pluripotency and EMT factors is concurrent with 
suppression of miRNAs, and the effect appears to abrogate xenograft tumor 
growth130-132,140. Despite these suggestive studies, the mechanism by which DCLK1 
is able to effectively regulate these processes remains unknown.  
One possible explanation for DCLK1’s broad effects on EMT, stemness, and 
miRNAs, is a signaling cascade set off by DCLK1’s regulation of either EMT inhibitor 
miR-200 or ZEB1, which form a positive feedback loop35,36,148. EMT and 
hypothesized CSC transdifferentiation15,149 could occur downstream of this loop, 
explaining many functional effects of DCLK1 overexpression or downregulation. 
Analysis of TCGA RNA-Seq and miRNA-Seq data provide support for a strong 
correlation between DCLK1 and EMT’s molecular signature in GI cancers57,100,150-
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152, with the exception of liver cancer (FIGURE 10A). In colon adenocarcinoma, 
which shows the most correlation, expression of EMT’s signature is mutually 
exclusive with low expression of DCLK1 (FIGURE 10B), and inverse correlations 
with each miR-200 isoform and DCLK1, as well as corresponding positive and 
negative correlations with EMT and epithelial markers respectively, are present 
(FIGURE 10C). 
Another possible explanation for DCLK1’s functional activity in cancer is its 
involvement in RAS signaling, which could have implications in pancreatic, 
colorectal, and lung adenocarcinoma, and other cancers. Not only does KRAS 
activation specifically upregulate DCLK1, but downregulating the expression of 
KRAS with shRNA results in a dose-dependent decrease in DCLK1153. Although 
FIGURE 10. DCLK1 associates with miR-200 and EMT in GI cancer. A. Analysis of 
DCLK1 and EMT signature expression shows strong correlation in all GI cancers with the 
exception of hepatocellular carcinoma. B. Alluvial plot demonstrating that in colon 
adenocarcinoma, high EMT levels (>75th percentile) are mutually exclusive with low 
DCLK1. C. DCLK1 is inversely correlated with the miR-200 EMT inhibitor family (a-c) and 
shows expected positive and negative associations with EMT/mesenchymal and epithelial 
genes respectively. 
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this KRAS-mediated regulation is driven transcriptionally, a recent study 
demonstrated that DCLK1 interacts with mutant KRAS and found significant 
homology between its N-terminal domain and RAS effector RalGDS142. If confirmed, 
these findings may describe a KRAS-DCLK1 feedback loop that explains regulation 
of DCLK1 expression by members of MAPK/ERK pathway downstream of 
KRAS142,154-157. Given a recent study demonstrating that KRAS activation 
suppresses the miR-200 EMT inhibitor family158, it is tempting to speculate that 
DCLK1’s interactions with the aforementioned miR-200-ZEB1-EMT axis and 
RAS/MAPK may be directly connected.  
Perhaps the most important aspect of DCLK1’s function that remains to be fully 
understood is the activity of its kinase. This is complicated by the multiple isoforms 
of DCLK1 with varying subcellular localizations and functions. For isoforms 
containing a microtubule-binding domain, some evidence suggests that their kinase 
activity and phosphorylation may impair their ability to polymerize microtubules159,160. 
Additionally, although a few substrates including MAP7D1, synapsin I and II, and 
JDP2161,162 have been identified, a role for these in DCLK1’s tumor function is 
unknown. Going forward, determining the specific function of DCLK1’s kinase 
activity may elucidate its role in cancer163 and the recently solved crystal structure 
for this domain159 may aid in this task. 
Overall, DCLK1 and the DCLK1+ tuft cell’s homeostatic function, lineage 
characteristics, response to injury and DNA damage, demonstrated role in tumor 
initiation and maintenance, and ability to drive EMT and invasion are logically 
connected and deserve continued investigation (FIGURE 11). Opportunities to 
target either DCLK1 or the DCLK1+ tuft cell are likely to emerge in the form of 
targeted antibodies, gene therapies, kinase inhibitors, and other innovative 
therapies. To fully realize these opportunities, an improved understanding of DCLK1 
and the tuft cell will be necessary. 
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FIGURE 11. A hypothetical etiology of inflammation-associated intestinal tumors. 
Intestinal stem cells (ISCs) (A) produce every cell in the intestinal epithelium – antibiotic 
secreting paneth cells (B), hormone secreting enteroendocrine cells (C), mucin secreting 
goblet cells (D), absorptive enterocytes (E), and chemosensory and IL-25 and opioid-
secreting tuft cells (F) which are marked by the expression of DCLK1. In the presence of 
significant injury (G), DNA damage is inflicted on the cells of the crypt (H) in response to 
which, tuft cells demonstrate significant resistance (I), and are tasked with orchestrating the 
response of the innate immune system. In this capacity, tuft cells secrete IL-25 which 
ultimately recruits immune cells that initiate tuft cell hyperplasia (J) through secretion of IL-
4/13. Due to the resistance that makes this process possible and their quiescence and long-
lived nature, tuft cells are exposed to DNA-damage and may escape apoptosis leading to 
mutation. A mutation to the tuft cell in the presence of inflammation is sufficient to transform 
the tuft cell into a cancer stem cell (K) that is able to produce the lineages of the primary 
tumor (L). As the tumor progresses, the expression of DCLK1 is a major contributing factor 
to EMT and may support intravasation (M) as evidenced by the expression of DCLK1 in 
circulating tumor cells.  
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4   Aims of the PhD investigation 
Given the significance of DCLK1 and the DCLK1+ tuft cell in GI injury and 
tumorigenesis, the following Aims were developed to further understanding of the 
role of DCLK1 in these processes, and are the subject of this PhD study: 
 
1) Determine if Dclk1 can foster resistance to DNA damage-inducing 
epithelial injury in the gastrointestinal tract. Dclk1 is specifically 
expressed in tuft cells in the intestinal epithelium which resist destruction 
following injury115. Because epithelial injury is an important source of 
oncogenic transformation, determining whether Dclk1 is a functional 
mediator of this resistance, rather than just a marker of the resistant cell, is 
key to understanding how tuft cells become CSCs. 
[Papers 5.1, 5.2] 
  
2) Determine if inhibitors of DCLK1 kinase activity have DCLK1-specific 
therapeutic potential in gastrointestinal cancers. DCLK1 is expressed in 
all gastrointestinal cancers10,70,120,136,140,157,164 and specifically marks tumor-
initiating, CSCs in the colon10,12 and pancreas142. RNA-interference targeting 
DCLK1 shows promising effects in vitro and in vivo130-132,140, but gene 
therapies for solid tumors are in the early stages of development and it 
remains to be seen whether this therapeutic concept will become clinically 
feasible. Conversely, kinase inhibitors are a class of drugs that are 
extensively used in cancer therapy with beneficial results. 
[Paper 5.3] 
 
3) Assess DCLK1’s potential as a biomarker in gastrointestinal cancers. 
Biomarkers that can predict the presence of or severity of disease are 
desperately needed in clinical practice. As a specific CSC marker in colon 
and pancreatic cancer, DCLK1 has the potential to predict the predilection 
for recurrence or metastasis, response to therapy, and other traits associated 
with CSCs. 
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[Papers 5.4, 5.5] 
 
4) Assess DCLK1 as a potential cancer stem cell marker or therapeutic 
target in cancers outside of the gastrointestinal tract. The functional 
significance of DCLK1 in gastrointestinal cancers is established, but there is 
limited knowledge about its role in other cancers. A number of tissue types 
demonstrate apparent tuft cells and the sensory and secretory function that 
DCLK1 contributes to in the gastrointestinal tract may be important in organs 
such as the lungs, breast, and urinary tract. 
[Paper 5.6] 
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5   Results and Discussion 
5.1 Doublecortin-like kinase 1 deletion in tuft cells results 
in impaired epithelial repair after radiation injury 
Background 
Radiation injury is a risk factor for some GI cancers, and experimentally it is valuable 
as a direct method for studying the effects of DNA damage and DDR – a process 
that results in the rapid accumulation of mutations and eventually may give rise to 
tumor-initiating cells. In the intestine, the radiation injury model is pertinent to the 
study of the origin and fate of cells, and is especially advantageous because the 
kinetics of the intestinal radiation response are well known165. The first study to 
assess DCLK1’s role outside of the brain made extensive use of this model115 and 
although it led to incorrect conclusions about the nature of DCLK1+ cells in the 
intestine, the findings of this study may explain how they eventually become CSCs. 
When exposed to sub-lethal doses of radiation (e.g. 6 Gy), DCLK1+ cells accumulate 
DNA damage as evidenced by the expression of phosphorylated histone H2AX. 
However, unlike surrounding DNA-damaged cells, some DCLK1+ cells escape 
apoptosis. This effect is overcome at lethal doses of radiation (>8 Gy)115. Therefore, 
understanding DCLK1’s role in the intestinal epithelial response to DNA-damage 
may have implications for its role in the tuft cell and in the development of cancer.  
Cre/flox mouse models allow specific events to be driven at the promoter level 
including gene knockout, activation, and cellular lineage tracing (FIGURE 5). 
Compared to conventional knock-in or knockout mouse models, this allows 
monitoring of events that occur at the organ, tissue, or cellular level to be examined 
specifically in vivo. Although conventional constitutive global knockouts of Dclk1 
have previously been reported in the literature and assessed from the standpoint of 
neurobiology, tissue compartment specific models of Dclk1 knockout had not 
previously been established. 
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Summary of Results 
Cross-breeding of intestinal epithelial-specific VillinCre mice with mice with loxP 
flanked Dclk1 exon 3 (Dclk1flox/flox)109, which is present in a-promoter isoforms of 
DCLK1 (AL/AS; FIGURE 7), led to excision of Dclk1 as confirmed by PCR of isolated 
intestinal epithelium. RNA-sequencing of isolated intestinal epithelial cells from the 
Dclk1 knockout mice demonstrated broad dysregulation of pathways including stem 
cell, notch signaling, tight junction, WNT, and sensory/secretory signaling. Induction 
of radiation injury after loss of Dclk1 in the intestinal epithelium led to dramatic 
consequences including loss of tight junctions, increased membrane permeability, 
decreased stem cell marker expression, impaired regeneration, and reduced 
survival times (approximately 5 days vs. 10 days for controls).  
 
Conclusion/Significance 
These results support a sensory/signaling role for tuft cell Dclk1 in maintaining the 
epithelium in injurious conditions and implicate it in GI cancer signaling pathways 
(stem cell, WNT, Notch). In combination with previous findings of intestinal epithelial 
Dclk1+ cell resistance to apoptosis following DNA damage115, a hypothetical 
pathway towards tumorigenesis is apparent (FIGURE 11).  
 
5.2 Ablation of doublecortin-like kinase 1 in the colonic 
epithelium exacerbates dextran sulfate sodium-induced 
colitis 
Background 
The response to epithelial injury is key to restoring normal tissue architecture and 
homeostasis in many organs. This is of particular importance in the crypt-villus axis 
of the intestine where stem cells that reside at the base of the crypt have the ability 
to rapidly replace all lineages of the epithelium. The tuft cell lineage of the intestine, 
marked by DCLK1, is able to resist radiation injury115 and is essential to survival 
afterwards as described in manuscript 5.1. However, acute and chronic 
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inflammation are far more common human diseases of the intestine, and conditions 
such as ulcerative colitis and Crohn’s disease predispose patients to CRC. 
Considering the DCLK1+ tuft cell’s transformation to a tumor-initiating, CSC under 
conditions of Apc loss10,136, determining its contribution to the development and 
progression of pre-cancerous inflammatory disease may provide insights into 
colorectal tumorigenesis.  
Colitis is linked to a number of factors including lifestyle, genetics, and infection. The 
response of the immune system to these events is perhaps the most important factor 
in the development of chronic colitis, precancerous lesions, and eventually 
cancer126,166. The DCLK1+ tuft cell is able to sense intestinal infection (perhaps via 
taste receptors125) and secrete IL-25 to recruit ILC2s and Th cells to the site of 
infection. Th cells then secrete IL-13 to recruit macrophages and IL-4 which results 
in tuft cell hyperplasia123,124. This process may form a surveillance feedback loop 
which is programmed to diminish when infection is eradicated. Given these aspects 
of the DCLK1+ tuft cell’s function, better understanding the role of the DCLK1 
gene/protein and its impact on inflammation and disease severity in colitis may 
improve our understanding of inflammation-associated intestinal tumorigenesis.  
 
Summary of Results 
Baseline characterization of the intestinal epithelial-specific knockout mouse model 
was in agreement with the results of manuscript 5.1. Following treatment with 
dextran sulfate sodium (DSS) to induce colitis, the knockout mice demonstrated 
decreased expression of epithelial/tight junction proteins and mucosal barrier 
integrity was compromised compared to control mice. To assess the consequences 
of the weakened barrier, direct and indirect inflammatory markers were assessed in 
the colon including myeloperoxidase (MPO) activity (a surrogate for neutrophil 
infiltration), cytokines, chemokines, and NF-kB tissue expression. Results revealed 
exacerbated inflammation and histological analysis showed decreased proliferation 
and increased apoptosis in Dclk1-knockout mice suggesting impaired regeneration 
after injury. Phenotypic assessment of the mice demonstrated more severe disease 
as measured by fecal blood, diarrhea, and weight loss. Finally, Dclk1-knockout mice 
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had poor survival compared to control mice which did not die through the duration 
of the study. 
 
Conclusion/Significance 
These findings provide further support for the conclusions of manuscript 5.1 in a 
more relevant model of injury. The Dclk1+ tuft cell’s sensory role in response to 
inflammation including immune recruitment and hyperplasia to increase surveillance 
may be key to maintaining mucosal barrier integrity. Conversely, the necessity of 
resistance in this cell and the tendency towards hyperplasia in DNA-damaging 
conditions117,123,124 is a potential source of tumorigenesis that remains to be fully 
elucidated.  
 
5.3 Small-molecule kinase inhibitor LRRK2-IN-1 
demonstrates potent activity against colorectal and 
pancreatic cancer through inhibition of doublecortin-like 
kinase 1 
Background 
Downregulation of DCLK1 gene expression with specific small-interfering RNAs 
(siRNAs) leads to reduced expression of pluripotency and EMT TFs130,131,140. On the 
functional level this manifests in decreased spheroid formation, cell invasion, cell 
migration, and other anti-cancer properties. In vivo delivery of DCLK1 siRNAs in 
nanoparticles results in highly decreased tumorigenesis in colon, pancreatic, and 
liver cancer xenografts131,132,140. Although these findings are promising, RNA 
interference technology has not been highly successful in the clinic to date. In 
contrast to RNA interference, kinase inhibition is an established therapeutic tool in 
oncology and widely used drugs (sunitinib, imatinib, erlotinib, etc.) function via this 
mechanism. Despite limited research into the role of DCLK1’s kinase activity in 
neurobiology, its potential as a kinase inhibitor target in cancer had not been 
previously assessed as inhibitors were not available. However, a kinome-wide 
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screen of the kinase inhibitor LRRK2-IN-1, which was developed to target the 
LRRK2 Parkinson’s disease kinase, demonstrated comparable affinity for DCLK1 
(approximately 5 nM Kd)167. 
 
Summary of Results 
An in vitro kinase assay confirmed that LRRK2-IN-1 was a DCLK1 kinase inhibitor 
with a low nanomolar IC50. Treatment of pancreatic (AsPC-1) and colon (HCT116) 
cancer cells with LRRK2-IN-1 resulted in apoptosis and cell death with an EC50 of 
1.69-1.73 µM as determined by MTT, LIVE/DEAD, and Caspase-3/7 assays. 
Moreover, immunocytochemistry of treated AsPC-1 cells demonstrated increased 
phosphohistone H3 expression and cell cycle analysis showed potent dose-
dependent G2/M arrest. LRRK2-IN-1 treatment also downregulated DCLK1 gene 
and protein expression which was hypothesized to be downstream of one of LRRK2-
IN-1’s other targets, MAPK7 (ERK5). In support of this hypothesis, treatment with 
the MEK1/2 inhibitor U0126 led to decreased expression of DCLK1. LRRK2-IN-1 
also demonstrated anti-metastatic effects including downregulation of EMT factor 
expression and inhibition of migration and invasion. To investigate if some of these 
anti-cancer effects could be ascribed to inhibition of DCLK1 kinase activity, we 
overexpressed wild-type DCLK1, kinase-dead DCLK1, and vector control (GFP) in 
cells and performed proliferation and colony formation assays. In both assays 
kinase-dead DCLK1 cells responded to LRRK2-IN-1 comparable to vector control 
cells while wild-type DCLK1 cells demonstrated resistance. Finally, to determine if 
LRRK2-IN-1 had potential as an in vivo anti-cancer agent, AsPC-1 xenografts were 
treated with a dose of 100 mg/kg on a fixed schedule which resulted in statistically 
significant tumor growth inhibition.  
 
Conclusion/Significance 
This was the first study to assess a DCLK1 kinase inhibitor as an anti-cancer therapy. 
Although the results were promising and new research with LRRK2-IN-1 is 
forthcoming168, significant off-target affinity for ERK5 complicates assigning specific 
activities to DCLK1. We overcame this with the use of a kinase-dead DCLK1 mutant 
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with moderate results. The finding that MEK1/2 inhibitor U0126 treatment results in 
downregulation of DCLK1 suggests that DCLK1’s role in this pathway should be 
further investigated and other groups have found indications that may suggest a 
feedback loop between DCLK1, MAPK/ERK pathway, and KRAS142,155. Given the 
findings of this and other studies with both LRRK2-IN-1 and analogue XMD8-92, 
there is a major need for the development of DCLK1 kinase inhibitors with less off-
target activity. 
 
5.4 Doublecortin-like kinase 1 is elevated serologically in 
pancreatic ductal adenocarcinoma and widely expressed 
on circulating tumor cells 
Background 
CSCs are known to influence drug and radiation resistance, recurrence and 
metastasis, and other tumor processes that impact survival and quality of 
life17,92,169,170. If it was possible to track the presence or activity of CSCs with direct 
or surrogate techniques, it may be possible to predict disease progression and 
survival. Moreover, monitoring CSCs using biomarkers may help determine whether 
or not therapy is necessary, the type and course of therapy, and the patient’s 
response to therapy. However, despite the potential benefits, biomarker 
development focused on CSCs has been limited. 
Immunohistochemical biomarkers are the most common markers used in the clinic. 
Examples include the widely-used proliferation marker Ki-67, breast cancer 
subtyping markers ER, PR and HER2/Neu, and EGFR, which are used to assess 
susceptibility to targeted therapies. However, although tissue biomarkers are useful, 
blood biomarkers are more desirable in most cases because they are minimally 
invasive and allow the monitoring of therapeutic efficacy and progression on a 
regular basis. Carbohydrate antigen 19-9 (CA19-9) is the most widely used serum 
biomarker in pancreatic cancer. However, research has shown that CA19-9 may be 
present in non-cancerous conditions which limits its use in the clinic171. Therefore, 
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a novel blood-based biomarker of sufficient specificity and accuracy in pancreatic 
cancer may have significant clinical utility. 
 
Summary of Results 
DCLK1 was upregulated in early (Stage I – II) pancreatic cancer but not in advanced 
disease. Receiver-operating characteristic (ROC) analysis of Stage I/II serum 
showed a modestly significant area under the curve of 0.74 suggesting that ELISA 
of serum DCLK1 was neither sensitive nor specific enough for use in this fashion. 
Western blotting of the serum samples confirmed those results. In comparison, 
CA19-9 serum levels were elevated in Stages II – IV but not Stage I in the same 
samples. Since the ELISA and western blotting techniques used to measure serum 
DCLK1 were denaturing, a related analysis was performed on circulating tumor cells 
(CTCs) from KPCY mice (PdxCreKrasLSL-G12DTp53LSL-R172HR26YFP) which mimic 
PDAC progression and metastasis and include a reporter (YFP) to track 
dissemination. YFP+ CTCs from the KPCY mice expressed Dclk1 approximately 40 
– 60% of the time, indicating a possibility that serum DCLK1 levels could be detected 
as a result of DCLK1+ CTCs. Moreover, tissue staining demonstrated DCLK1/YFP++ 
populations in metastatic tissues.  
 
Conclusion/Significance 
Overall, the findings of this study demonstrate that: 1) DCLK1 is detectable in human 
serum; 2) DCLK1 is upregulated in Stage I-II PDAC patient serum but 
indistinguishable from normal patients in Stage III-IV; 3) DCLK1 is expressed on 
PDAC CTCs; 4) DCLK1 may not be suitable as a diagnostic/prognostic serum 
biomarker for PDAC and the identification of relevant patient subgroups or better 
markers of its expression/activity are likely needed. 
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5.5 Survival of patients with gastrointestinal cancers can 
be predicted by a surrogate miRNA signature for cancer 
stem-like cells marked by doublecortin-like kinase 1 
Background 
The decoding of the human genome and resulting microarray and sequencing 
technologies provide an immense opportunity for advances in biomarker 
development. Whereas previous technologies were dependent on detecting a 
mutation or the expression of a single target, high throughput technologies make 
the development of multi-target biomarkers more feasible. Examples of these 
technologies in clinical use include the Oncotype DX™, PAM50 (Prosigna™), and 
Mammaprint™ array technologies which are used to predict recurrence in hormone-
receptor positive breast cancers172. Patients with a low score in these tests may be 
able to avoid prolonged chemotherapies which have unpleasant side-effects, 
including significant long-term risks in some cases.  
Multigene biomarkers may be particularly suitable for detection of CSC activity. 
Since CSCs are defined by their ability to self-renew and produce all progeny that 
comprise the tumor, it is feasible that a tumor with low CSC marker expression may 
produce more progeny than a comparable tumor with high CSC marker expression. 
Counterintuitively, the tumor with low CSC marker expression could potentially have 
more CSC activity and therefore more aggressiveness and adaptability to treatment 
than its counterpart. The Cancer Genome Atlas (TCGA) offers a novel platform to 
test this concept in terms of the DCLK1+ GI CSC. 
 
Summary of Results 
DCLK1 was expressed and strongly correlated to EMT across gastrointestinal 
cancer types (colon, esophagus, pancreatic, stomach, and rectal). However, in liver 
it was only correlated with mesenchymal but not epithelial gene expression. As a 
result, and due to the lack of similarities with other GI tumors, we excluded liver from 
further analysis. With the remaining cancers, correlation analysis was performed for 
DCLK1 and each gene in the transcriptome. The resulting consensus significant 
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genes between all cancer types were too numerous, which is consistent with 
overlapping functions for DCLK1+ cells across GI cancers, but impractical for 
deriving a biomarker. For further analysis, we turned to miRNAs which are stable 
analytes and limited in number. Correlation analysis for miRNAs identified 15 
significantly associated species including miR-200a/b which were previously 
reported to be regulated by DCLK1. For 5 of the miRNAs, real-time PCR analysis of 
miRNA expression demonstrated the predicted effect in both directions (e.g. DCLK1 
downregulation upregulates miR-200a, while DCLK1 does the reverse). Using 
standardized miRNA expression data, a signature score was calculated by 
subtracting the sum of downregulated miRNAs from the sum of upregulated miRNAs. 
The signature predicted overall survival in colon, pancreatic, and stomach cancers 
and recurrence in colon and stomach cancers. Finally, subgroup analysis identified 
patient groups that might benefit from prognostic use of the biomarker including 
early stage colon cancer patients who have survival consistent with advanced 
disease when presenting with high signature expression, and stomach cancer 
patients receiving radiotherapy who have significantly reduced survival with high 
signature expression. 
 
Conclusion/Significance 
The overall significance of this study falls into three different categories. Primarily, it 
identifies a surrogate biomarker for DCLK1 and consequently its activity. The import 
of this arises from the concept of CSCs which counterintuitively may diminish their 
own signal by producing diverse progeny in the tumor. The use of a surrogate 
signature may overcome insufficient sensitivity and specificity inherent to a singular 
CSC marker. Another significant aspect of this study is the methodology used to 
derive the marker itself. Instead of focusing on a single tumor type, a signature was 
derived across 5 tumor types that are known or suspected to contain DCLK1+ 
sensory epithelial cells and in which DCLK1 is correlated to EMT. Similar 
procedures may be applied to biomarker development for other targets using data 
from other platforms. Finally, the signature predicted survival in a number of cancer 
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types (colon, gastric, pancreatic) and in specific patient subgroups (e.g. early-stage 
colon cancer), and further development may yield a viable biomarker. 
 
5.6 Doublecortin-like kinase 1 is a broadly dysregulated 
target against epithelial-mesenchymal transition, focal 
adhesion, and stemness in clear cell renal carcinoma 
Background 
The urinary and gastrointestinal tracts are regions that are susceptible to microbial 
and chemical inflammation. Both tracts require extensive sensory, secretory, and 
absorptive capabilities to maintain the sensitive balance required for 
homeostasis74,173,174. An analysis of data available from TCGA suggested that of all 
cancers, DCLK1 was most overexpressed in ccRCC. This finding was of interest as 
DCLK1 was previously thought not to be expressed in the kidney175, suggesting 
potential tumor specificity. Moreover, RCC is characterized by its slow growth, 
hypoxic microenvironment, EMT, and potent resistance to chemotherapy40,176-178 – 
characteristics linked to CSCs16,17,149,179,180. However, the role of CSCs in kidney 
cancer has only been investigated to a limited extent. 
 
Summary of Results 
Analysis of TCGA’s ccRCC dataset revealed overexpression of DCLK1 in tumors 
compared to normal and matched adjacent normal tissue. Immunohistochemical 
staining showed a similar result with increased expression of DCLK1 in Stages II-III 
compared to Stage I or normal tissue. Hypomethylation of DCLK1 promoter regions 
in tumors versus matched normal tissue supported epigenetic dysregulation as a 
likely source of overexpression. DCLK1 downregulation led to significantly reduced 
expression of EMT factors, migration, and invasion. During migration analysis, 
increased space between cells was noted in cells transfected with DCLK1 siRNA. 
Image thresholding calculations, staining for focal adhesions (vinculin) and cell 
structure (filamentous actin), and western blotting revealed a loss of focal adhesion 
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mediated by downregulation of focal adhesion kinase (FAK/PTK2). Molecular 
analysis demonstrated downregulation of pluripotency factors and stem cell marker 
ALDH1A1, and functional stemness was significantly impaired as evidenced by 
much fewer and smaller spheroids after DCLK1 knockdown. 
 
Conclusion/Significance 
This was the first study to investigate DCLK1 outside of the GI tract or 
neuroblastoma. Previous studies had claimed incorrectly that DCLK1 was not 
expressed in the normal kidney, but immunohistochemical tissue staining showed it 
present in some tubules where there is some potential for a sensory role, and in the 
kidney stroma. The results of this study demonstrate that DCLK1 can have a 
comparable oncogenic role (e.g. EMT, stemness, etc.) to its GI cancer role in other 
tumor types, and necessitate further study of whether DCLK1 may also mark CSCs 
or CSC-like cells in kidney and other urinary tract cancers.  
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6   Conclusions and Future Directions 
The work presented here covers novel findings in four specific areas of research 
and comprises a body of work focused on DCLK1. Since the publication of these 
works, DCLK1 has emerged as a prominent CSC-related marker in many cancers 
including non-GI tract cancers. Although Dclk1 was discredited as a normal or 
reserve stem cell marker at homeostasis or in injury, the work in gut biology outlined 
in this thesis (5.1 & 5.2)181,182 helped establish Dclk1 as a sensory factor and 
regulator of the response to epithelial injury – a finding that provides additional 
support for studies that show the Dclk1+ tuft cell orchestrating the immune response 
to parasitic invasion123-125 and implicate Dclk1 in inflammation-mediated cancer10,142. 
In the area of cancer therapies, the work presented here was the first to demonstrate 
the potential for DCLK1-targeted kinase inhibitors against gastrointestinal 
cancers183 (5.3). Improving on these existing inhibitors for DCLK1 selectivity may be 
a promising avenue for the development of novel therapies with significant clinical 
potential. Success in this area may also necessitate further development of DCLK1-
based biomarkers. The data reported here suggest that DCLK1 serological levels 
may not be useful as clinical diagnostic or prognostic biomarkers in GI tract 
cancers184 (5.4), though exploring these levels in select patient subgroups including 
early-stage patients may yet prove promising. However, the work presented here 
utilizing RNA-Seq data shows that surrogate multi-gene biomarkers may be able to 
fill this role185 (5.5). Finally, findings of DCLK1 as an overexpressed drug target and 
potential CSC marker in kidney cancer186 may be relevant to research in RCC and 
other non-GI cancers (5.6). Although previous work had suggested oncogenic 
properties of DCLK1 in neuroblastoma, this work was the first to look at its role in 
EMT and stemness in non-GI cancers. Overall, DCLK1 is rapidly emerging as a 
deleterious factor in many non-GI cancers133,143,145,155,187,188.  
On a technological level, advances in single-cell RNA sequencing technologies 
have already begun to revolutionize our understanding of tuft cells, revealing distinct 
origins for the cell type in the colon and small intestine189, suggesting the presence 
of a separate immune-regulatory tuft cell type190, and providing an atlas that can be 
used for confirming results and cross-referencing other data. Whether these and 
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other murine studies will have the expected relevance in human systems will likely 
be revealed as the Human Cell Atlas begins progress in characterizing the cells of 
the GI tract under conditions of homeostasis, infection, and neoplasia. These 
advances may also improve our understanding of CTCs which DCLK1 marks in 
several cancers184,188,191-193.  
Although studies have proven the potential of epigenetic biomarkers, only a single 
marker is currently approved in the US (SEPT9 for CRC diagnosis)194. Analyses of 
DCLK1 methylation suggests that it may have potential as a diagnostic 
biomarker186,188,195-197, but the hypermethylation of its a-promoter has also been a 
source of controversy as it relates to the nature of DCLK1’s isoforms. This has led 
some to propose a tumor suppressor function for some isoforms and an 
oncogenic/CSC function for others195. Studies to methodically characterize the 
activity of each isoform will ultimately be necessary to decode DCLK1’s interactions 
and its upstream and downstream signaling. It is notable that virtually all studies in 
the GI tract or cancer have focused on a-promoter isoforms, and the activity of the 
b-promoter driven isoforms are not well known. To overcome this issue, the 
development of a b-promoter DCLK1-driven Cre or comparable mouse model may 
be necessary.  
Finally, although DCLK1 is a CSC marker in mouse models, it will be important to 
determine how applicable this finding is to human patients. Based on findings using 
the stem cell/CSC marker LGR5198, the development of DCLK1-specific organoid 
culture from human colorectal, pancreatic, and other tumors may be feasible and 
could provide advantages over other models, or be used as a personalized therapy 
platform. However, the most important work to determine the relevance of DCLK1 
to human cancer is likely the development of DCLK1-targeted therapies. This may 
be in the form of monoclonal antibodies that take advantage of the unusual 
membrane localization of some of its isoforms199, specific kinase inhibitors, novel 
gene therapies such as chimeric antigen receptor T cells (CAR-T), or other 
modalities that may improve outcomes in patients. 
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8   Appendix I. 
 
8.1    Epidemiology and classification of select tumors 
Table I. World Health Organization/IARC Guidelines for TNM Staging (T)1-2. 
 
 
Table II. World Health Organization/IARC Guidelines for TNM Staging (N)1-2. 
 
 
Table III. World Health Organization/IARC Guidelines for TNM Staging (M)1-2. 
 
 
 
 
T Classification T1 T2 T3 T4
Colorectal Tumor invading the colorectal submucosa
Tumor invading the muscularis 
propria
Tumor invading through the 
subserosa or non-peritoneal 
surrounding tissues
Tumor invading any other organs 
or tissue structures or invading 
through to the peritoneal cavity
Pancreatic Pancreas localized tumor < 2 cm at longest diameter
Pancreas localized tumor >2cm 
at longest diameter
Tumor invading the duodenum, 
bile duct, or any other 
surrounding tissue
Tumour invading directly into the 
stomach, spleen, colon, or nearby 
large vessels
Gastric Tumor invades gastric lamina propria or submucosa
Tumor invades muscularis propria 
or subserosa
Tumor invading through serosa 
without invading adjacent tissue Tumor invading adjacent tissue
Esophageal Tumor invades esophageal lamina propria or submucosa Tumor invades muscularis propria Tumor invades adventitia Tumor invading adjacent tissue
Kidney Tumor < 7 cm at longest diameter Tumor > 7 cm but kidney localized
Tumor invading major veins, 
adrenal gland, or surrounding 
tissue in renal/adrenal 
compartment
Tumor invading beyond the 
renal/adrenal compartment 
("Gerota fascia")
N Classification N1 N2 N3
Colorectal Metastasis in 1-3 local lymph nodes
Metastasis in >3 local lymph 
nodes N/A
Pancreatic Metastasis in 1 (N1a) or more (N1b) local lymphnodes N/A N/A
Gastric Metastasis in 1-6 local lymph nodes
Metastasis in 7-15 local lymph 
nodes
Metastasis in >15 local lymph 
nodes
Esophageal Metastasis in local lymph node N/A N/A
Kidney Metastasis in 1 local lymph node Metastasis in >1 local lymph node N/A
M Classification M1
Colorectal Distant metastasis
Pancreatic Distant metastasis
Gastric Distant metastasis
Esophageal
Distant metastasis in celiac lymph 
node (M1a) or anywhere else 
(M1b)
Kidney Distant metastasis
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Table IV. World Health Organization/IARC Guidelines for TNM Staging 
(Stage)1-2. 
 
 
Table V. Incidence, Mortality, and Characteristics of Select Tumors1-4. 
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Staging Stage I Stage II Stage III Stage IV
Colorectal T1-2 N0 M0 T3-4 N0 M0 T1-4 N1-2 M0 T-4 N0-2 M1
Pancreatic T1-2 N0 M0 T3 N0 M0 T1-3 N1 M0 T4 N0-1 M0 or T1-4 N0-1 M1
Gastric T1-2 N0-1 M0 T1/N2 or T2/N1 or T3/N0 + M0
T2/N2 or T3/N1 or 
T4/N0 + M0
T4 N1-3 or T1-3 N3 + 
M0/T1-4 N0-3 M1
Esophageal T1 N0 M0 T2-3 N0 M0 T1-3 N1 M0 or T4 N0-1 M0 T1-4 N0-1 M1
Kidney T1 N0 M0 T2 N0 M0 T3 N0 M0 or T1-3 N1 M0
T4 N0-1 or T1-4 N2 + 
M0/T1-4 N0-2 M1
Category Locale Colorectal Pancreatic Gastric Esophageal Kidney
Incidence (per 100,000 
persons) US 40.1 12.5 7.3 4.2 15.6
UK 85.0 19.7 14.1 18.7 25.7
Mortality (per 100,000 
persons) US 14.8 10.9 3.2 4.1 3.9
UK 33.2 18.1 9.8 16.4 9.3
5-Year Survival (%) US 64.9 8.2 30.6 18.8 74.1
UK 59 3 19 15 56
Common Subtypes
Adenocarcinoma, 
Mucinous 
Adenocarcinoma
Adenocarcinoma, 
Acinar Cell, Intraductal 
Papillary Mucinous 
Neoplasm
Adenocarcinoma Adenocarcinoma, 
Squamous Cell 
Clear Cell, Papillary, 
Chromophobe
Major Risk Factors
Tobacco, Radiation, 
Red Meat, Alcohol, 
Physical Inactivity, 
Obesity , IBD
Tobacco, Obesity, 
Chronic Pancreatitis, 
Chemicals, Diabetes
Tobacco, Radiation, H. 
pylori , Preserved 
Foods, Chemicals
Tobacco, Radiation, 
Chemical Exposure, 
Alcohol, Obesity, 
HPV, Esophagitis
Tobacco, Obesity, 
Hypertension
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